Literature DB >> 11007042

p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.

L A Erickson1, O M Yousef, L Jin, C M Lohse, V S Pankratz, R V Lloyd.   

Abstract

In most cases, the histopathologic and cytologic distinction between Graves' disease and papillary thyroid carcinoma is relatively easy, but on occasion Graves' disease may simulate a thyroid papillary carcinoma. For example, papillary fronds with fibrovascular cores may be present in both Graves' disease and papillary carcinoma. p27kip1 (p27) is a cyclin-dependent kinase inhibitory protein that has been shown to be an independent prognostic factor in a variety of human tumors. Our previous studies of p27 expression in hyperplastic and neoplastic endocrine lesions showed that the level of p27 was quite different in these two conditions. To determine if this distinction could also be made between Graves' disease and papillary carcinoma, we analyzed expression of p27 and other cell cycle proteins in a series of cases of Graves' disease with papillary hyperplasia and a series of papillary thyroid carcinomas. Formalin-fixed paraffin-embedded tissues from 61 randomly selected patients with thyroid disease, including 29 cases of Graves' disease with papillary architectural features and 32 cases of papillary carcinoma, were analyzed for expression of p27, Ki-67, and DNA topoisomerase II alpha (topo II alpha) by immunostaining. The distribution of immunoreactivity was analyzed by quantifying the percentage of positive nuclei that was expressed as the labeling index (LI) plus or minus the standard error of the mean. The papillary hyperplasia of Graves' disease had a p27 LI of 68.2 +/- 3.1 (range, 24 to 88), whereas papillary carcinomas had a LI of 25.6 +/- 2.5 (range, 12 to 70) (P < .0001). No significant differences in Ki-67 or topo II alpha expression were identified between papillary hyperplasia in Graves' disease and papillary carcinoma. These results indicate that p27 protein expression is significantly higher in papillary hyperplasia of Graves' disease compared to papillary carcinoma, which may be diagnostically useful in difficult cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007042     DOI: 10.1038/modpathol.3880182

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

Review 1.  The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia.

Authors:  Simon J Raphael
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

2.  Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma.

Authors:  G Troncone; A Iaccarino; M Russo; E A Palmieri; M Volante; M Papotti; G Viglietto; L Palombini
Journal:  J Clin Pathol       Date:  2006-06-23       Impact factor: 3.411

3.  Significance of AgNORs and ki-67 proliferative markers in differential diagnosis of thyroid lesions.

Authors:  Hayam A Aiad; Manar A Bashandy; Asmaa G Abdou; Ahmad A Zahran
Journal:  Pathol Oncol Res       Date:  2012-10-11       Impact factor: 3.201

4.  p27kip1 expression is inversely related to the grade of gastric MALT lymphoma.

Authors:  Haim Shirin; Vladimir Kravtsov; Mark Shahmurov; Paulina Petchenko; Mona Boaz; Steven F Moss; Yona Avni; Ilana Avinoach
Journal:  Int J Gastrointest Cancer       Date:  2005

5.  p27 Kip1 protein expression in Hashimoto's thyroiditis.

Authors:  G Troncone; A Iaccarino; A Caleo; D Bifano; G Pettinato; L Palombini
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

6.  Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.

Authors:  Mary B Casey; Christine M Lohse; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

7.  Tunicamycin enhances TRAIL-induced apoptosis by inhibition of cyclin D1 and the subsequent downregulation of survivin.

Authors:  Hai-Yan Zhang; Zhen-Xian Du; Bao-Qin Liu; Yan-Yan Gao; Xin Meng; Yifu Guan; Wei-Wei Deng; Hua-Qin Wang
Journal:  Exp Mol Med       Date:  2009-05-31       Impact factor: 8.718

8.  Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.

Authors:  Young Joo Park; Soo Heon Kwak; Dong Chul Kim; Haeryoung Kim; Gheeyoung Choe; Do Joon Park; Hak Chul Jang; Seong Hoe Park; Bo Youn Cho; So Yeon Park
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

9.  The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.

Authors:  A Ferru; G Fromont; H Gibelin; J Guilhot; F Savagner; J M Tourani; J L Kraimps; C J Larsen; L Karayan-Tapon
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

10.  Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.

Authors:  Huairong Zhang; Bo Gao; Bingyin Shi
Journal:  Dis Markers       Date:  2016-09-15       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.